Valens GroWorks Commences Cannabis Oil Production

On , In Press Releases

Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products, is pleased to announce the successful completion of its initial batch of supercritical CO2-extracted cannabis oil at wholly-owned subsidiary Valens AgriTech in Kelowna.

The Company’s current 400 kg per month processing capacity is expected to increase to 1,000 kg over March, and to 6,000 kg per month with the addition of several double-capacity machines, scheduled for delivery starting mid-March.

Solvent selection is very important for applications in the food, nutraceutical, and pharmaceutical industries, where health and safety legislation place severe restrictions on the types of solvents that can be used. Supercritical CO2 removes the concern of toxic solvent residues in our products. CO2 extracts are pure and require minimal post-processing. Carbon dioxide is generally recognized as safe by the FDA and EFSA, making CO2 the ideal solvent for processing food and medical extracts.

Valens’ utilization of a full-spectrum extraction process allows greater control and tuneability for multiple throughputs and sales objectives, is closed-loop so the evaporating CO2 is captured and reused, and extracts a significant amount of the terpenes in cannabis, the fragrant oils that give cannabis its aromatic diversity.

Terpenes are secreted in the flower’s sticky resin glands, the same ones that produce THC, CBD, and other cannabinoids. Lab-testing is the only way of knowing a strain’s terpene potency. Valens’ oils will be continuously batch-tested through Supra THC Services, our in-house Health Canada licensed cannabis testing lab, to assure the highest quality and content essential to our branding objectives.

About Valens GroWorks

Valens GroWorks is a multi-licensed, vertically integrated provider of Canadian cannabis products with two wholly-owned subsidiaries located in Kelowna, BC. Subsidiary Valens Agritech has initiated cannabis production, processing and sales under a Health Canada Dealers Licence, which includes a supply agreement with Canopy Growth Corporation (TSX:WEED) under their extensive CraftGrow distribution network. Subsidiary Supra THC Services is a Health Canada licensed cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant Based Medicine Analytics. For more information, please visit https://valensgroworks.com, http://www.valensagritech.com and http://www.suprathc.ca.

On behalf of the Board of Directors,
VALENS GROWORKS CORP.

(signed) “Tyler Robson”
Chief Executive Officer

For further information, please contact:
Greg Patchell
Telephone: +1.250.860.8634

Notice Regarding Forward Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections
contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

Download .PDF